Moderna (MRNA) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moderna (MRNA) has outperformed Revolution Medicines (RVMD) over the past year, gaining 605.6% versus a gain of 293.4%. Over five years, RVMD leads with a +598.0% price change compared with -39.2% for MRNA. Moderna is the larger company by market cap ($78.65 billion vs $40.32 billion), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | RVMD |
|---|---|---|
| Share price | $197.00 | $188.12 |
| Market cap | $78.65B | $40.32B |
| 1-day change | +0.26% | -6.35% |
| YTD return | +568.02% | +136.18% |
| 1-year return | +605.59% | +293.39% |
| 5-year return | -39.24% | +598.03% |
| EPS (TTM) | $-7.98 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.94B | $0 |
| Revenue growth (YoY) | -39.93% | — |
| Net income (latest FY) | $-2.82B | $-1.13B |
| Gross margin | 55.35% | — |
| Operating margin | -158.13% | — |
| Net margin | -145.16% | — |
| 52-week high | $212.22 | $224.31 |
| 52-week low | $22.28 | $47.28 |
| Distance from 52-week high | -7.17% | -16.13% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -38.58% | +37.59% |
| Average volume | 17.44M | 1.88M |
| Shares outstanding | 399.24M | 214.34M |
| Employees | 4,700 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRNA has outperformed RVMD by 312.2 percentage points over the past year.
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
MRNA vs RVMD FAQ
Which is bigger, Moderna or Revolution Medicines?
Moderna (MRNA) is larger, with a market capitalization of $78.65B compared with $40.32B for Revolution Medicines (RVMD).
Which stock has performed better over the past year, MRNA or RVMD?
MRNA returned +605.59% over the past 12 months, compared with +293.39% for RVMD (price return, excluding dividends). Past performance does not predict future results.
Are Moderna and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.